north@ Every time Vascepa/Vaszeka - is related/compared to Fish Oils Amarin - AMRN has a problem.
And it is indeed THE PROBLEM - for this drug in the long run - to distinguish itself from OTC Fish Oils. ---------------------------
When I first joined here 'hate figure' number one were Adam Feuerstein (with a take on AMRN on $7 - at a point where average was above $30 from analysts). This last period it has been Steven Nissen - for his attach's on the R-I trail.
I never understood why Amarin didn't - counter attach - in using Niassen results Positive in relation to Vascepa. What Nissen in fact did - were to Prove - that OTC ordinary Fish Oil (EPA-DHA) - Do NOT benefit CDV patients. That way actually Underscoring - why Amarin developed a drug Purely based on purified EPA - org. for lowering trigs - but then noticed the big general improvements in health that were finally proved through the major 5 year long study called Reduce-IT.
Nissen Proved that Vascepa - is NOT Fish Oil - 'Use It' my friends :) -------------------------
Finishing on Fish Oils - what we all have to understand IS' that we are up against very big Market Forces - far to big for Amarin to take on - in the short run. Way to go is - Ever and Again - to distinguish Vascepa/Vaskepa from this market - in fact 100% the truth - Vascepa is a processed, purified Drug - that has no reassembles with traditional OTC Fish oils what so ever.
Comparing Vascepa/Vaszeka - to any kind of ordinary OTC Fish Oils 'is noncence' which Amarin and the rest of us has to inform the World. And apart form that' stay away from debating the subject. -------------------------
North There is a lack of differentiation between "omega-3" and specifically EPA Icosapent Ethyl--this is a problem. Also, there is contamination by analysis for sudden arrhythmogenic sudden cardiac death which is quite another beast compared to MI CVA CV death.. HK
News 
Market Data 
Discover 
